Premium
Low‐dose combination chemotherapy for acute myeloid leukemia in elderly patients: A novel approach
Author(s) -
Manoharan Arumugam,
Baker Ross I.,
Kyle Peter W.
Publication year - 1997
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/(sici)1096-8652(199706)55:2<115::aid-ajh12>3.0.co;2-d
Subject(s) - cytarabine , medicine , etoposide , myeloid leukemia , chemotherapy , gastroenterology , leukemia , myeloid , complete remission , oncology , surgery
Eighteen patients aged 60‐84 years with acute myeloid leukemia were treated with low‐dose combination chemotherapy comprising cytarabine, etoposide, and mitozantrone or 6‐thioguanine; seven of these patients had a pre‐existing myelodysplastic syndrome. Nine patients achieved a complete remission, and five had a partial remission. The duration of survival in these 14 responding patients has ranged from 2+ to 19+ months. Myelotoxicity occurred regularly, with time to recovery (neutrophils ≥0.5 × 10 9 /L, platelets ≥50 × 10 9 /L) from nadir being 10‐14 days in 12 of the 14 patients. This novel approach with an overall response rate of 78% appears to be a simple and effective form of therapy for elderly patients. Am. J. Hematol. 55:115‐117, 1997. © 1997 Wiley‐Liss, Inc.